<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27956398</article-id><article-id pub-id-type="pmc">5210434</article-id><article-id pub-id-type="doi">10.1161/JAHA.116.003957</article-id><article-id pub-id-type="publisher-id">JAH31918</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Arrhythmia and Electrophysiology</subject></subj-group></subj-group></article-categories><title-group><article-title>Neurohormonal Activation After Atrial Fibrillation Initiation in Patients Eligible for Catheter Ablation: A Randomized Controlled Study</article-title><alt-title alt-title-type="left-running-head">Charitakis et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah31918-cr-0001" contrib-type="author" corresp="yes"><name><surname>Charitakis</surname><given-names>Emmanouil</given-names></name><degrees>MD</degrees><address><email>mcharitakis@gmail.com</email></address><xref ref-type="aff" rid="jah31918-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31918-cr-0002" contrib-type="author"><name><surname>Walfridsson</surname><given-names>H&#x000e5;kan</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah31918-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31918-cr-0003" contrib-type="author"><name><surname>Nylander</surname><given-names>Eva</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah31918-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah31918-cr-0004" contrib-type="author"><name><surname>Alehagen</surname><given-names>Urban</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah31918-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jah31918-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Cardiology and Department of Medical and Health Sciences</named-content><institution>Link&#x000f6;ping University</institution><named-content content-type="city">Link&#x000f6;ping</named-content><country country="SE">Sweden</country></aff><aff id="jah31918-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Department of Clinical Physiology and Department of Medical and Health Sciences</named-content><institution>Link&#x000f6;ping University</institution><named-content content-type="city">Link&#x000f6;ping</named-content><country country="SE">Sweden</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Emmanouil Charitakis, MD, Department of Cardiology, Link&#x000f6;ping University Hospital, Garnisonsv&#x000e4;gen 10, 581 85 Link&#x000f6;ping, Sweden. E&#x02010;mail: <email>mcharitakis@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2016</year></pub-date><volume>5</volume><issue>12</issue><issue-id pub-id-type="doi">10.1002/jah3.2016.5.issue-12</issue-id><elocation-id>e003957</elocation-id><history><date date-type="received"><day>25</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>08</day><month>11</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-5-e003957.pdf"/><abstract id="jah31918-abs-0001"><sec id="jah31918-sec-0001"><title>Background</title><p>Biomarker activation in atrial fibrillation (<styled-content style="fixed-case">AF</styled-content>) has been widely studied, but the immediate effect of <styled-content style="fixed-case">AF</styled-content> initiation remains unclear. We studied the effect of <styled-content style="fixed-case">AF</styled-content> initiation on 2 cardiac biomarkers: the N&#x02010;terminal fragment of the proB&#x02010;type natriuretic peptide (<styled-content style="fixed-case">NT</styled-content>&#x02010;pro<styled-content style="fixed-case">BNP</styled-content>), the midregional fragment of the N&#x02010;terminal of pro&#x02010;atrial natriuretic peptide (<styled-content style="fixed-case">MR</styled-content>&#x02010;pro<styled-content style="fixed-case">ANP</styled-content>), and 2 extracardiac biomarkers&#x02014;the copeptin and the midregional portion of proadrenomedullin (<styled-content style="fixed-case">MR</styled-content>&#x02010;pro<styled-content style="fixed-case">ADM</styled-content>).</p></sec><sec id="jah31918-sec-0002"><title>Methods and Results</title><p>This was a randomized controlled study, including 45 patients with <styled-content style="fixed-case">AF</styled-content> who had been referred for radiofrequency ablation to the University Hospital, Link&#x000f6;ping, Sweden, between February 2012 and April 2014. Freedom from <styled-content style="fixed-case">AF</styled-content> during the 4&#x000a0;days prior to radiofrequency ablation was confirmed by transtelephonic <styled-content style="fixed-case">ECG</styled-content>s. Biomarkers were collected from the femoral vein (fv), coronary sinus (<styled-content style="fixed-case">CS</styled-content>), and left atrium (<styled-content style="fixed-case">LA</styled-content>) prior to <styled-content style="fixed-case">AF</styled-content> initiation (baseline) and 30&#x000a0;minutes later. The <styled-content style="fixed-case">MR</styled-content>&#x02010;pro<styled-content style="fixed-case">ANP</styled-content> and <styled-content style="fixed-case">NT</styled-content>&#x02010;pro<styled-content style="fixed-case">BNP</styled-content> concentrations increased in the intervention group compared with the control group 30&#x000a0;minutes after the initiation of <styled-content style="fixed-case">AF</styled-content> (<styled-content style="fixed-case">MR</styled-content>&#x02010;pro<styled-content style="fixed-case">ANP</styled-content>:<italic> P</italic>
<sub>fv</sub>&#x0003c;0.001, <italic>P</italic>
<sub>CS</sub>&#x0003c;0.001, <italic>P</italic>
<sub>LA</sub>&#x0003c;0.001; <styled-content style="fixed-case">NT</styled-content>&#x02010;pro<styled-content style="fixed-case">BNP</styled-content>:<italic> P</italic>
<sub>LA</sub>&#x0003c;0.001). Copeptin levels in patients without ischemic heart disease were decreased after the initiation of <styled-content style="fixed-case">AF</styled-content> (<italic>P</italic>
<sub>fv</sub>=0.003, <italic>P</italic>
<sub>CS</sub>=0.015, <italic>P</italic>
<sub>LA</sub>=0.011).</p></sec><sec id="jah31918-sec-0003"><title>Conclusions</title><p>
<styled-content style="fixed-case">AF</styled-content> is a strong stimulus that results in immediate activation of different biomarkers.</p></sec><sec id="jah31918-sec-0004"><title>Clinical Trial Registration</title><p>
<styled-content style="fixed-case">URL</styled-content>: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>. Unique identifier: <styled-content style="fixed-case">NCT</styled-content>01553045.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah31918-kwd-0001">atrial fibrillation</kwd><kwd id="jah31918-kwd-0002">biomarkers</kwd><kwd id="jah31918-kwd-0003">radiofrequency ablation</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Arrhythmias</kwd></kwd-group><funding-group><award-group><funding-source>ALF</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Carldavid J&#x000f6;nsson Research Foundation</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Heart Foundation</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Link&#x000f6;ping University</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Biosense Webster</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Johnson &#x00026; Johnson</funding-source></award-group></funding-group><counts><fig-count count="6"/><table-count count="5"/><page-count count="12"/><word-count count="7937"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah31918</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.0 mode:remove_FC converted:23.12.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah31918-cit-1001">(<source>J Am Heart Assoc</source>. <year>2016</year>;<volume>5</volume>:e003957 doi: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.116.003957">10.1161/JAHA.116.003957</ext-link>)</mixed-citation>
</p></notes></front><body><sec id="jah31918-sec-0005"><title>Introduction</title><p>Atrial fibrillation (AF) is the most common cardiac arrhythmia, with an estimated prevalence of 2.9% in the Swedish population.<xref rid="jah31918-bib-0001" ref-type="ref">1</xref> Both cardiac and extracardiac biomarkers have been associated with clinical events in patients with AF.<xref rid="jah31918-bib-0002" ref-type="ref">2</xref>
</p><p>The 2 cardiac biomarkers&#x02014;the atrial and the N&#x02010;terminal proB&#x02010;type natriuretic peptide (ANP and NT&#x02010;proBNP, respectively)&#x02014;are synthesized and secreted from atrial and ventricular myocytes<xref rid="jah31918-bib-0003" ref-type="ref">3</xref> in response to increased wall tension.<xref rid="jah31918-bib-0004" ref-type="ref">4</xref> Although the most common cause of increased NT&#x02010;proBNP production is heart failure (HF), elevated concentrations of NT&#x02010;proBNP have been reported in patients with AF even without overt HF.<xref rid="jah31918-bib-0005" ref-type="ref">5</xref> Moreover, in a community&#x02010;based population, NT&#x02010;proBNP indicated a substantial risk of developing AF.<xref rid="jah31918-bib-0006" ref-type="ref">6</xref> ANP and its precursor protein proANP have not been pursued in clinical studies because they are prone to fragmentation, which means plasma levels can be underestimated.<xref rid="jah31918-bib-0007" ref-type="ref">7</xref> Therefore, a stable method for quantifying the midregional fragment of proANP (MR&#x02010;proANP) was introduced,<xref rid="jah31918-bib-0007" ref-type="ref">7</xref> and the biomarker seems to correlate with the duration of AF episodes.<xref rid="jah31918-bib-0008" ref-type="ref">8</xref>
</p><p>Furthermore, there are some extracardiac biomarkers of potential interest in AF. For example, arginine vasopressin (AVP) is an important hormone for the fluid regulation of the body. The plasma concentration of vasopressin increases in patients with HF due to inadequate cardiac output or low blood pressure and increased vascular resistance.<xref rid="jah31918-bib-0009" ref-type="ref">9</xref>, <xref rid="jah31918-bib-0010" ref-type="ref">10</xref> The C&#x02010;terminal fragment of provasopressin (copeptin) is released in equimolar amounts to AVP and is easier to determine.<xref rid="jah31918-bib-0011" ref-type="ref">11</xref> Thus, copeptin can serve as a surrogate marker for AVP secretion. Copeptin has proved to be a prognostic biomarker in patients with HF<xref rid="jah31918-bib-0009" ref-type="ref">9</xref>, <xref rid="jah31918-bib-0012" ref-type="ref">12</xref> and an additional biomarker to conventional troponin to rule out myocardial infarction (MI) early when a highly sensitive troponin assay is not available.<xref rid="jah31918-bib-0013" ref-type="ref">13</xref>
</p><p>Adrenomedullin (ADM), an extracardiac peptide with vasoactive and natriuretic properties, has also emerged as a biomarker of potential interest in the prediction of cardiovascular disease risks.<xref rid="jah31918-bib-0014" ref-type="ref">14</xref> It is secreted mainly from the adrenal medulla and endothelial cells in response to several hormonal agents and physical stimulants, such as shear stress and stretch.<xref rid="jah31918-bib-0015" ref-type="ref">15</xref>, <xref rid="jah31918-bib-0016" ref-type="ref">16</xref>, <xref rid="jah31918-bib-0017" ref-type="ref">17</xref>, <xref rid="jah31918-bib-0018" ref-type="ref">18</xref> Due to the short half&#x02010;life of ADM and its immediate binding to receptors, its evaluation in clinical routines is impractical. The MR&#x02010;proADM, a product of the parental molecule of ADM, is stable and therefore better suited for clinical use.<xref rid="jah31918-bib-0019" ref-type="ref">19</xref> Recent research has shown that MR&#x02010;proADM levels predict the recurrence of AF after radiofrequency ablation (RFA).<xref rid="jah31918-bib-0020" ref-type="ref">20</xref>
</p><p>Even though these biomarkers have been widely studied in the context of cardiovascular disease and to some extent in AF, to the best of our knowledge, no study has previously evaluated the immediate effect of AF initiation.</p><p>The aim of this study is to investigate the response of the biomarkers MR&#x02010;proANP, NT&#x02010;proBNP, copeptin, and MR&#x02010;proADM immediately after the initiation of AF in patients eligible for RFA and in sinus rhythm (SR) prior to the procedure.</p></sec><sec id="jah31918-sec-0006"><title>Methods</title><sec id="jah31918-sec-0007"><title>Study Design</title><p>This is a randomized, controlled, parallel, single&#x02010;center study with an allocation ratio of 2:1 in favor of the interventional group. It is the interventional part of the Symptom burden, Metabolic profile, Ultrasound findings, Rhythm, neurohormonal activation, hemodynamics and health&#x02010;related quality of life in patients with atrial Fibrillation (SMURF) study. The design of the SMURF study has been previously presented.<xref rid="jah31918-bib-0021" ref-type="ref">21</xref>
</p></sec><sec id="jah31918-sec-0008"><title>Participants</title><p>The study was conducted between February 2012 and April 2014. All patients with AF referred for RFA to the University Hospital in Link&#x000f6;ping, Sweden, were eligible for participation. The inclusion criteria were: (1) patients older than 17&#x000a0;years with paroxysmal or persistent AF, (2) patients referred to the hospital for first&#x02010;time RFA treatment, and (3) with sufficient knowledge of the Swedish language to fill out the study questionnaires independently.</p><p>Exclusion criteria were patients (1) who previously had undergone catheter or surgical AF ablation, (2) with previous or expected heart surgery, (3) with severe HF with left ventricular (LV) ejection fraction (EF) &#x0003c;35%, (4) with acute coronary syndrome during the past 3&#x000a0;months, and (5) with 1 or more arrhythmia episodes in the 4&#x02010;day period prior to RFA.</p><p>The Regional Ethical Review Board in Link&#x000f6;ping, Sweden, approved the protocol (Registration number 2011/40&#x02010;31). All patients gave their written informed consent, and the study participation was documented in the patient's medical record. The study complies with the Declaration of Helsinki.<xref rid="jah31918-bib-0022" ref-type="ref">22</xref>
</p></sec><sec id="jah31918-sec-0009"><title>Transtelephonic ECG</title><p>The transtelephonic ECG registrations were performed twice a day and if symptoms occurred. All ECGs were sent by telephone to a centralized, secure socket layer encrypted digital ECG database on the Internet that can only be accessed by authorized personnel. Rhythm analysis was performed prior to the randomization of eligible patients. The rhythm was classified into the following categories: SR, AF, atrial tachycardia, or &#x0201c;not specified rhythm.&#x0201d;</p><p>The system used for this study was developed by Zenicor AB (Stockholm, Sweden) and consisted of a device that can register a short ECG sequence (30&#x000a0;seconds) by placing the thumbs on 2 measuring plates. The method was validated<xref rid="jah31918-bib-0023" ref-type="ref">23</xref> and used in order to improve the screening of silent AF in patients with ischemic stroke<xref rid="jah31918-bib-0024" ref-type="ref">24</xref> and as an event recorder.</p></sec><sec id="jah31918-sec-0010"><title>Ablation Procedure</title><p>The procedures were performed under conscious sedation as described previously.<xref rid="jah31918-bib-0021" ref-type="ref">21</xref> The endpoint of the procedure was an electrical disconnection of all pulmonary veins by antral ablation verified by both entry and exit blocks. In patients with persistent AF, additional ablation was performed in order to create left atrial (LA) lines at the discretion of the operator and verified by pacing maneuvers.</p></sec><sec id="jah31918-sec-0011"><title>Biomarkers</title><p>Blood samples were collected in plastic vials containing ethylenediaminetetraacetic acid (EDTA). The vials were centrifuged at 3100<italic>g</italic> for 20&#x000a0;minutes at 4&#x000b0;C and then frozen at &#x02212;70&#x000b0;C. No sample was thawed more than twice.</p><p>The concentrations of proBNP<sub>1&#x02010;76</sub> (NT&#x02010;proBNP) were measured on the Elecsys 2010 platform (Roche Diagnostics, Mannheim, Germany). The total coefficient of variation (CV) was 4.6% at 426.5&#x000a0;pg/mL (n=487) and 3.2% at 2308&#x000a0;pg/mL (n=495). Plasma concentrations of MR&#x02010;proADM, copeptin, and MR&#x02010;proANP were measured on the Kryptor platform (Brahms AG, Hennigsdorf, Germany). The total CV for copeptin was 4% at a concentration of 15&#x000a0;pmol/L (n=18) and 3.5% at a concentration of 100&#x000a0;pmol/L (n=18). According to the manufacturer, the intra&#x02010;assay CV for MR&#x02010;proADM was &#x02264;10% for concentrations between 0.2 and 0.5&#x000a0;nmol/L, less than 4%&#x000a0;for concentrations between 0.5 and 2&#x000a0;nmol/L, less than 2% for concentrations between 2 and 6&#x000a0;nmol/L, and less than&#x000a0;3.5% for concentrations over 6&#x000a0;nmol/L. The intra&#x02010;assay CV for MR&#x02010;proANP, according to the manufacturer, was &#x02264;5% for concentrations between 10 and 20&#x000a0;pmol/L, less than 3.5% for concentrations between 20 and 1000&#x000a0;pmol/L, and less than 3.5% for concentrations over 1000&#x000a0;pmol/L.</p></sec><sec id="jah31918-sec-0012"><title>Subject Measurements</title><p>The subject measurements of the study have been described previously.<xref rid="jah31918-bib-0021" ref-type="ref">21</xref> In brief, after screening, the eligible patients received written information about the study and were provided with transtelephonic ECG devices. They were instructed to record and send ECG recordings twice daily and extra recordings if any symptoms of arrhythmia occurred during the 4&#x02010;day period prior to RFA.</p><p>Prior to RFA, the patients received further oral information and signed an informed consent form and were thereby included in the SMURF study. A full baseline evaluation, including medical history, physical examination, and a 12&#x02010;lead ECG, was recorded. All patients underwent transthoracic and transesophageal echocardiogram and a computed tomographic scan of the heart, according to the clinical routine.</p><p>All registered transtelephonic ECGs sent by the patients were screened, and if these were free from arrhythmias, the respective patients were eligible for randomization.</p><p>All patients were catheterized according to clinical routine, and blood samples were drawn from the femoral vein, CS, and LA (baseline sampling) for the analysis of NT&#x02010;proBNP, MR&#x02010;proANP, copeptin, and MR&#x02010;proADM. The catheter position in CS was evaluated in the left anterior oblique projection.</p></sec><sec id="jah31918-sec-0013"><title>Intervention</title><p>After baseline blood sampling and intracardiac pressure measurements, the patients randomized to the active group had AF induced with burst pacing from CS (with cycle length, CL, of 170&#x02010;300&#x000a0;milliseconds). AF was maintained for 30&#x000a0;minutes and was immediately reinduced when necessary; thereafter, the blood samples were drawn for biomarker analysis.</p><p>The patients randomized to the control group were monitored for 30&#x000a0;minutes in SR after the baseline measurements. Then, new blood samples were drawn.</p><p>After the interventional part of the study, RFA was performed as described previously.<xref rid="jah31918-bib-0021" ref-type="ref">21</xref> At the end of the procedure, blood samples were drawn from the peripheral vein for biomarker analysis.</p></sec><sec id="jah31918-sec-0014"><title>Primary Endpoint</title><p>The primary endpoints were changes in MR&#x02010;proANP, NT&#x02010;proBNP, MR&#x02010;proADM, and copeptin concentrations after the AF initiation compared with the controls in 3 sample sites, ie, the femoral vein, LA, and CS.</p></sec><sec id="jah31918-sec-0015"><title>Randomization</title><p>The participants were randomized with a 2:1 allocation ratio at the time of catheterization, ie, for every 2 patients randomized to AF initiation, 1 patient was randomized to the control group. Due to the nature of the intervention, blinding of participants or staff was not possible.<xref rid="jah31918-bib-0021" ref-type="ref">21</xref>
</p></sec><sec id="jah31918-sec-0016"><title>Sample Size</title><p>This study was preceded by a small pilot study observing the reaction of MR&#x02010;proANP 30&#x000a0;minutes after the initiation of AF. The MR&#x02010;proANP concentration was 174&#x000a0;pmol/L (95% confidence interval [CI] 45&#x02010;218&#x000a0;pmol/L) at baseline and 253 (64&#x02010;308&#x000a0;pmol/L) 30&#x000a0;minutes after AF initiation. The results indicated that 29 patients were required in order to find a statistically significant difference in the MR&#x02010;proANP reaction with a power of 90% and type&#x02010;1 error of 0.05. However, we increased the number of participants to 45 because we chose another study design (control randomized study) with allocation ratio 2:1, 3 additional biomarkers were tested, the Benjamini&#x02010;Hochberg procedure<xref rid="jah31918-bib-0025" ref-type="ref">25</xref> was chosen in order to avoid false discoveries due to multiple testing, and possible dropouts were taken into account. The sample size calculation was performed by using a commercially available statistical analysis software package (STATISTICA 10; Statsoft, Dell STATISTICA, Tulsa, OK).</p></sec><sec id="jah31918-sec-0017"><title>Statistical Methods</title><p>For baseline characteristics, continuous variables were expressed as means&#x000b1;standard deviation (SD). Variables that did not have a Gaussian distribution were presented as medians with interquartile range (IQR). Categorical data were presented as counts and percentages. Possible differences in the baseline characteristics between the randomized groups were tested using a t test for normally distributed data, a Mann&#x02010;Whitney U test for nonparametric data, and chi&#x02010;squared for categorical data.</p><p>In order to analyze the primary endpoints, a repeated&#x02010;measures analysis of variance (ANOVA) was used. Time with 2 levels (baseline and 30&#x000a0;minutes after the AF initiation) was used as a within&#x02010;subjects factor, the randomized group was used as a between&#x02010;subjects factor, and changes in biomarkers' levels in the randomized groups over time were studied (time&#x000d7;randomization). A subgroup analysis for patients without ischemic heart disease (IHD) was also performed.</p><p>Logarithmic transformation (log<sub>10</sub>) of NT&#x02010;proBNP, MR&#x02010;proANP, and copeptin levels was used because these biomarkers were not normally distributed. NT&#x02010;proBNP, MR&#x02010;proANP, and the copeptin levels were presented as geometric means with a 95% CI. MR&#x02010;proADM levels were presented as means with a 95% CI because these were normally distributed.</p><p>The repeated&#x02010;measures ANOVA was corrected concerning NT&#x02010;proBNP for the covariates of heart rate at baseline and age, that concerning MR&#x02010;proANP for the covariate ejection fraction &#x0003c;50%, and that concerning copeptin for the covariate of age.</p><p>All reported <italic>P</italic> values were 2&#x02010;sided, and a <italic>P</italic>&#x0003c;0.05 was considered statistically significant. In order to avoid any false discoveries due to multiple testing, the Benjamini&#x02010;Hochberg procedure<xref rid="jah31918-bib-0025" ref-type="ref">25</xref> was used. The analyses were performed using SPSS 22.0 (SPSS, Chicago, IL).</p></sec></sec><sec id="jah31918-sec-0018"><title>Results</title><sec id="jah31918-sec-0019"><title>Participant Flow</title><p>During the period from February 2012 to April 2014, 338 patients with AF were referred to the Department of Cardiology at the University Hospital in Link&#x000f6;ping, Sweden, and were accepted for first&#x02010;time RFA. The inclusion period was closed when the planned number of participants was achieved. The inclusion and randomization flowchart is presented in Figure&#x000a0;<xref rid="jah31918-fig-0001" ref-type="fig">1</xref>.</p><fig fig-type="Figure" xml:lang="en" id="jah31918-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Inclusion and randomization flowchart. <styled-content style="fixed-case">AF</styled-content> indicates atrial fibrillation; <styled-content style="fixed-case">EF</styled-content>, ejection fraction; pts, patients; <styled-content style="fixed-case">RFA</styled-content>, radiofrequency ablation; SMURF, Symptom burden, Metabolic profile, Ultrasound findings, Rhythm, neurohormonal activation, hemodynamics and health&#x02010;related quality of life in patients with atrial Fibrillation.</p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-5-e003957-g001"/></fig></sec><sec id="jah31918-sec-0020"><title>Baseline Characteristics</title><p>The study population consisted of 33 men and 12 women with a median age of 59 (IQR 14) years. The mean procedural time was 3&#x000a0;hours and 15&#x000a0;minutes, and the mean fluoroscopy time was 21&#x000a0;minutes. There were no significant differences in the baseline characteristics or baseline biomarker levels between the groups (Tables&#x000a0;<xref rid="jah31918-tbl-0001" ref-type="table-wrap">1</xref> and <xref rid="jah31918-tbl-0002" ref-type="table-wrap">2</xref>).</p><table-wrap id="jah31918-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline Characteristics of the 2 Randomized Groups (Control and Intervention Groups)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Variables</th><th align="left" valign="top" rowspan="1" colspan="1">Control Group (N=16)</th><th align="left" valign="top" rowspan="1" colspan="1">Induction Group (N=29)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, y</td><td align="left" rowspan="1" colspan="1">58 (IQR, 15)</td><td align="left" rowspan="1" colspan="1">62 (IQR, 12.8)</td><td align="left" rowspan="1" colspan="1">0.104</td></tr><tr><td align="left" rowspan="1" colspan="1">Female sex</td><td align="left" rowspan="1" colspan="1">5 (31%)</td><td align="left" rowspan="1" colspan="1">7 (24%)</td><td align="left" rowspan="1" colspan="1">0.429</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">25.8 (IQR, 5.2)</td><td align="left" rowspan="1" colspan="1">26.4 (IQR, 7.2)</td><td align="left" rowspan="1" colspan="1">0.749</td></tr><tr><td align="left" rowspan="1" colspan="1">Paroxysmal AF</td><td align="left" rowspan="1" colspan="1">7 (44%)</td><td align="left" rowspan="1" colspan="1">14 (49%)</td><td align="left" rowspan="1" colspan="1">0.509</td></tr><tr><td align="left" rowspan="1" colspan="1">Months in AF</td><td align="left" rowspan="1" colspan="1">36 (IQR, 96)</td><td align="left" rowspan="1" colspan="1">54 (IQR, 93)</td><td align="left" rowspan="1" colspan="1">0.778</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of DC conversions/patient with persistent AF</td><td align="left" rowspan="1" colspan="1">4.2&#x000b1;2.2</td><td align="left" rowspan="1" colspan="1">4.9&#x000b1;3.9</td><td align="left" rowspan="1" colspan="1">0.627</td></tr><tr><td align="left" rowspan="1" colspan="1">Heredity<xref ref-type="fn" rid="jah31918-note-0003">a</xref>
</td><td align="left" rowspan="1" colspan="1">9 (56%)</td><td align="left" rowspan="1" colspan="1">10 (35%)</td><td align="left" rowspan="1" colspan="1">0.109</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">9 (56%)</td><td align="left" rowspan="1" colspan="1">9 (31%)</td><td align="left" rowspan="1" colspan="1">0.091</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" rowspan="1" colspan="1">1 (6%)</td><td align="left" rowspan="1" colspan="1">2 (7%)</td><td align="left" rowspan="1" colspan="1">0.715</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart failure<xref ref-type="fn" rid="jah31918-note-0004">b</xref>
</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2 (7%)</td><td align="left" rowspan="1" colspan="1">0.283</td></tr><tr><td align="left" rowspan="1" colspan="1">CKD (GFR &#x0003c;60&#x000a0;mL/min per 1.73&#x02009;m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">4 (25%)</td><td align="left" rowspan="1" colspan="1">3 (10%)</td><td align="left" rowspan="1" colspan="1">0.194</td></tr><tr><td align="left" rowspan="1" colspan="1">SVT</td><td align="left" rowspan="1" colspan="1">1 (6%)</td><td align="left" rowspan="1" colspan="1">3 (10%)</td><td align="left" rowspan="1" colspan="1">0.644</td></tr><tr><td align="left" rowspan="1" colspan="1">TIA</td><td align="left" rowspan="1" colspan="1">2 (13%)</td><td align="left" rowspan="1" colspan="1">1 (3%)</td><td align="left" rowspan="1" colspan="1">0.244</td></tr><tr><td align="left" rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>VASc</td><td align="left" rowspan="1" colspan="1">2 (IQR, 3)</td><td align="left" rowspan="1" colspan="1">1 (IQR, 2)</td><td align="left" rowspan="1" colspan="1">0.203</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003b2;&#x02010;Blocker</td><td align="left" rowspan="1" colspan="1">10 (66%)</td><td align="left" rowspan="1" colspan="1">17 (59%)</td><td align="left" rowspan="1" colspan="1">0.799</td></tr><tr><td align="left" rowspan="1" colspan="1">AAD</td><td align="left" rowspan="1" colspan="1">4 (25%)</td><td align="left" rowspan="1" colspan="1">14 (48%)</td><td align="left" rowspan="1" colspan="1">0.127</td></tr><tr><td align="left" rowspan="1" colspan="1">Amiodarone</td><td align="left" rowspan="1" colspan="1">3 (19%)</td><td align="left" rowspan="1" colspan="1">6 (21%)</td><td align="left" rowspan="1" colspan="1">0.876</td></tr><tr><td align="left" rowspan="1" colspan="1">Flecainide</td><td align="left" rowspan="1" colspan="1">3 (19%)</td><td align="left" rowspan="1" colspan="1">7 (24%)</td><td align="left" rowspan="1" colspan="1">0.677</td></tr><tr><td align="left" rowspan="1" colspan="1">Dronedarone</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1 (3%)</td><td align="left" rowspan="1" colspan="1">0.453</td></tr><tr><td align="left" rowspan="1" colspan="1">ACEi or ARB</td><td align="left" rowspan="1" colspan="1">7 (44%)</td><td align="left" rowspan="1" colspan="1">7 (24%)</td><td align="left" rowspan="1" colspan="1">0.174</td></tr><tr><td align="left" rowspan="1" colspan="1">Aldosterone receptor antagonist</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2 (6.9%)</td><td align="left" rowspan="1" colspan="1">0.283</td></tr><tr><td align="left" rowspan="1" colspan="1">Other diuretics</td><td align="left" rowspan="1" colspan="1">3 (19%)</td><td align="left" rowspan="1" colspan="1">4 (14%)</td><td align="left" rowspan="1" colspan="1">0.661</td></tr><tr><td align="left" rowspan="1" colspan="1">Statins</td><td align="left" rowspan="1" colspan="1">3 (19%)</td><td align="left" rowspan="1" colspan="1">10 (35%)</td><td align="left" rowspan="1" colspan="1">0.265</td></tr><tr><td align="left" rowspan="1" colspan="1">HR baseline, bpm</td><td align="left" rowspan="1" colspan="1">59&#x000b1;13</td><td align="left" rowspan="1" colspan="1">60&#x000b1;12</td><td align="left" rowspan="1" colspan="1">0.871</td></tr><tr><td align="left" rowspan="1" colspan="1">Procedural time, minute</td><td align="left" rowspan="1" colspan="1">187&#x000b1;35</td><td align="left" rowspan="1" colspan="1">199&#x000b1;43</td><td align="left" rowspan="1" colspan="1">0.338</td></tr><tr><td align="left" rowspan="1" colspan="1">Fluoroscopy time, minute</td><td align="left" rowspan="1" colspan="1">20.8&#x000b1;9.6</td><td align="left" rowspan="1" colspan="1">21.1&#x000b1;6.4</td><td align="left" rowspan="1" colspan="1">0.893</td></tr><tr><td align="left" rowspan="1" colspan="1">Fluoroscopy dose, cGycm<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">2260 (IQR, 3061)</td><td align="left" rowspan="1" colspan="1">1521 (IQR, 1567)</td><td align="left" rowspan="1" colspan="1">0.245</td></tr><tr><td align="left" rowspan="1" colspan="1">Total delivered RF energy, J</td><td align="left" rowspan="1" colspan="1">65&#x000a0;427&#x000b1;19&#x000a0;669</td><td align="left" rowspan="1" colspan="1">65&#x000a0;209&#x000b1;22&#x000a0;493</td><td align="left" rowspan="1" colspan="1">0.974</td></tr><tr><td align="left" rowspan="1" colspan="1">Complications</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1 (3%)</td><td align="left" rowspan="1" colspan="1">0.453</td></tr><tr><td align="left" rowspan="1" colspan="1">Primary successful procedure</td><td align="left" rowspan="1" colspan="1">16 (100%)</td><td align="left" rowspan="1" colspan="1">27 (93%)</td><td align="left" rowspan="1" colspan="1">0.283</td></tr><tr><td align="left" rowspan="1" colspan="1">EF (biplane)</td><td align="left" rowspan="1" colspan="1">63&#x000b1;4</td><td align="left" rowspan="1" colspan="1">61&#x000b1;5</td><td align="left" rowspan="1" colspan="1">0.348</td></tr></tbody></table><table-wrap-foot><fn id="jah31918-note-0002"><p>Normally distributed variables are presented as mean values&#x000b1;SD, nonparametric variables are presented as median values with IQR, and categorical data are presented as counts and percentages. Results from t tests for normally distributed variables, chi&#x02010;squared for categorical variables, and Mann&#x02010;Whitney U for nonparametric variables are presented, and <italic>P</italic>&#x0003c;0.05 is considered statistically significant. AAD indicates antiarrhythmic drugs; ACEi, angiotensin&#x02010;converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin&#x02010;2 receptor blocker; BMI, body mass index; CHA<sub>2</sub>DS<sub>2</sub>VASc, congestive heart failure, hypertension, age &#x0003e;75&#x000a0;years, diabetes mellitus, stroke, vascular disease, female sex; CKD, chronic kidney disease; EF, ejection fraction; GFR, glomerular filtration rate; HR, heart rate; IQR, interquartile range; N, number of patients; SD, standard deviation; SVT, supraventricular tachycardia; TIA, transient ischemic attack.</p></fn><fn id="jah31918-note-0003"><label>a</label><p>First&#x02010;degree relatives with AF.</p></fn><fn id="jah31918-note-0004"><label>b</label><p>EF &#x0003c;50%.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><table-wrap id="jah31918-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline Biomarker Concentrations in Both Randomized Groups</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Control Group</th><th align="left" valign="top" rowspan="1" colspan="1">95% CI</th><th align="left" valign="top" rowspan="1" colspan="1">Intervention Group</th><th align="left" valign="top" rowspan="1" colspan="1">95% CI</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NT&#x02010;proBNP<sub>fv (pg/mL)</sub>
</td><td align="left" rowspan="1" colspan="1">97.5</td><td align="left" rowspan="1" colspan="1">61.1 to 155.7</td><td align="left" rowspan="1" colspan="1">63.9</td><td align="left" rowspan="1" colspan="1">45.1 to 90.5</td><td align="left" rowspan="1" colspan="1">0.138</td></tr><tr><td align="left" rowspan="1" colspan="1">NT&#x02010;proBNP<sub>CS (pg/mL)</sub>
</td><td align="left" rowspan="1" colspan="1">144.4</td><td align="left" rowspan="1" colspan="1">87 to 239.8</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">58.1 to 115.7</td><td align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">NT&#x02010;proBNP<sub>LA (pg/mL)</sub>
</td><td align="left" rowspan="1" colspan="1">94.3</td><td align="left" rowspan="1" colspan="1">59 to 150.8</td><td align="left" rowspan="1" colspan="1">61.4</td><td align="left" rowspan="1" colspan="1">43 to 87.5</td><td align="left" rowspan="1" colspan="1">0.134</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proANP<sub>fv (pmol/L)</sub>
</td><td align="left" rowspan="1" colspan="1">114.6</td><td align="left" rowspan="1" colspan="1">77.9 to 151.3</td><td align="left" rowspan="1" colspan="1">98.4</td><td align="left" rowspan="1" colspan="1">82.8 to 113.9</td><td align="left" rowspan="1" colspan="1">0.342</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proANP<sub>CS (pmol/L)</sub>
</td><td align="left" rowspan="1" colspan="1">151.5</td><td align="left" rowspan="1" colspan="1">116.1 to 197.8</td><td align="left" rowspan="1" colspan="1">132.5</td><td align="left" rowspan="1" colspan="1">105.9 to 165.9</td><td align="left" rowspan="1" colspan="1">0.451</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proANP<sub>LA (pmol/L)</sub>
</td><td align="left" rowspan="1" colspan="1">100.9</td><td align="left" rowspan="1" colspan="1">79.5 to 128.1</td><td align="left" rowspan="1" colspan="1">95.7</td><td align="left" rowspan="1" colspan="1">79.2 to 115.5</td><td align="left" rowspan="1" colspan="1">0.721</td></tr><tr><td align="left" rowspan="1" colspan="1">Copeptin<sub>fv (pmol/L)</sub>
</td><td align="left" rowspan="1" colspan="1">6.68</td><td align="left" rowspan="1" colspan="1">4.95 to 9.01</td><td align="left" rowspan="1" colspan="1">8.21</td><td align="left" rowspan="1" colspan="1">5.5 to 12.27</td><td align="left" rowspan="1" colspan="1">0.471</td></tr><tr><td align="left" rowspan="1" colspan="1">Copeptin<sub>CS (pmol/L)</sub>
</td><td align="left" rowspan="1" colspan="1">7.19</td><td align="left" rowspan="1" colspan="1">5.38 to 9.62</td><td align="left" rowspan="1" colspan="1">9.05</td><td align="left" rowspan="1" colspan="1">5.86 to 14</td><td align="left" rowspan="1" colspan="1">0.464</td></tr><tr><td align="left" rowspan="1" colspan="1">Copeptin<sub>LA (pmol/L)</sub>
</td><td align="left" rowspan="1" colspan="1">6.71</td><td align="left" rowspan="1" colspan="1">4.85 to 9.28</td><td align="left" rowspan="1" colspan="1">8.03</td><td align="left" rowspan="1" colspan="1">5.33 to 12.1</td><td align="left" rowspan="1" colspan="1">0.721</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proADM<sub>fv (nmol/L)</sub>
</td><td align="left" rowspan="1" colspan="1">0.654</td><td align="left" rowspan="1" colspan="1">0.565 to 0.734</td><td align="left" rowspan="1" colspan="1">0.583</td><td align="left" rowspan="1" colspan="1">0.53 to 0.636</td><td align="left" rowspan="1" colspan="1">0.134</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proADM<sub>CS (nmol/L)</sub>
</td><td align="left" rowspan="1" colspan="1">0.636</td><td align="left" rowspan="1" colspan="1">0.547 to 0.724</td><td align="left" rowspan="1" colspan="1">0.563</td><td align="left" rowspan="1" colspan="1">0.513 to 0.613</td><td align="left" rowspan="1" colspan="1">0.115</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proADM<sub>LA (nmol/L)</sub>
</td><td align="left" rowspan="1" colspan="1">0.577</td><td align="left" rowspan="1" colspan="1">0.508 to 0.645</td><td align="left" rowspan="1" colspan="1">0.544</td><td align="left" rowspan="1" colspan="1">0.495 to 0.593</td><td align="left" rowspan="1" colspan="1">0.414</td></tr></tbody></table><table-wrap-foot><fn id="jah31918-note-0005"><p>NT&#x02010;proBNP, MR&#x02010;proANP, and copeptin levels are presented as geometric means with 95% CI. MR&#x02010;proADM levels are presented as means with 95% CI. Results from t tests are presented, and <italic>P</italic>&#x0003c;0.05 is considered statistically significant. CI indicates confidence interval; CS, coronary sinus; fv, femoral vein; LA, left atrium; LAm, left atrium mean pressure; MR&#x02010;proADM, midregional portion of proadrenomedullin; MR&#x02010;proANP, midregional fragment of the N&#x02010;terminal precursor of atrial natriuretic peptide; NT&#x02010;proBNP, N&#x02010;terminal fragment of prodromal B&#x02010;type natriuretic peptide.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>We were unable to catheterize CS in 6 patients. However, no statistically significant differences were observed between those 6 patients and the 39 patients from whom blood samples were collected from CS (Table&#x000a0;S1).</p><p>The patients in whom AF was induced were found to have increased HR by 43&#x000a0;beats/min, whereas HR in the control group did not change significantly.</p><p>One patient in the intervention group suffered from a cardiac tamponade requiring pericardiocentesis. This complication took place during the RFA, ie, after both baseline blood sampling and the blood sample collection 30&#x000a0;minutes after the intervention. This was the only complication observed.</p></sec><sec id="jah31918-sec-0021"><title>AF Initiation and Its Effect on Cardiac Biomarkers</title><sec id="jah31918-sec-0022"><title>MR&#x02010;proANP</title><p>Compared with the baseline, the MR&#x02010;proANP concentrations showed an increase of 73% in the femoral vein, 70% in CS, and 79% in LA in the intervention group, 30&#x000a0;minutes after the initiation of AF. On the other hand, MR&#x02010;proANP concentrations in the control group showed a marginal increase of about 6% in all blood&#x02010;sampling locations. The MR&#x02010;proANP reactions of the intervention group were statistically significant when compared with the respective control group (femoral vein: <italic>P</italic>&#x0003c;0.001; CS, <italic>P</italic>&#x0003c;0.001; LA, <italic>P</italic>&#x0003c;0.001; Table&#x000a0;<xref rid="jah31918-tbl-0003" ref-type="table-wrap">3</xref> and Figure&#x000a0;<xref rid="jah31918-fig-0002" ref-type="fig">2</xref>).</p><table-wrap id="jah31918-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>NT&#x02010;proBNP, MR&#x02010;proANP, Copeptin, and MR&#x02010;proADM Reactions in Both Randomized Groups</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Baseline</th><th align="left" valign="top" rowspan="1" colspan="1">95% CI</th><th align="left" valign="top" rowspan="1" colspan="1">30&#x000a0;Minutes After Induction</th><th align="left" valign="top" rowspan="1" colspan="1">95% CI</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
<sub>time&#x000d7;randomization</sub>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NT&#x02010;proBNP<sub>int fv (pg/mL) n=29</sub>
</td><td align="left" rowspan="1" colspan="1">63.9</td><td align="left" rowspan="1" colspan="1">45.1 to 90.5</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46.5 to 93.8</td><td align="left" rowspan="2" colspan="1">0.073</td></tr><tr><td align="left" rowspan="1" colspan="1">NT&#x02010;proBNP<sub>con fv (pg/mL) n=16</sub>
</td><td align="left" rowspan="1" colspan="1">97.5</td><td align="left" rowspan="1" colspan="1">61.1 to 155.7</td><td align="left" rowspan="1" colspan="1">97.7</td><td align="left" rowspan="1" colspan="1">61.5 to 155.2</td></tr><tr><td align="left" rowspan="1" colspan="1">NT&#x02010;proBNP<sub>int CS (pg/mL) n=26</sub>
</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">58.1 to 115.7</td><td align="left" rowspan="1" colspan="1">92.7</td><td align="left" rowspan="1" colspan="1">69.4 to 123.9</td><td align="left" rowspan="2" colspan="1">0.882</td></tr><tr><td align="left" rowspan="1" colspan="1">NT&#x02010;proBNP<sub>con CS (pg/mL) n=13</sub>
</td><td align="left" rowspan="1" colspan="1">144.4</td><td align="left" rowspan="1" colspan="1">87 to 239.8</td><td align="left" rowspan="1" colspan="1">158.2</td><td align="left" rowspan="1" colspan="1">93.5 to 268</td></tr><tr><td align="left" rowspan="1" colspan="1">NT&#x02010;proBNP<sub>int LA (pg/mL) n=29</sub>
</td><td align="left" rowspan="1" colspan="1">61.4</td><td align="left" rowspan="1" colspan="1">43 to 87.5</td><td align="left" rowspan="1" colspan="1">65.3</td><td align="left" rowspan="1" colspan="1">46.2 to 92.3</td><td align="left" rowspan="2" colspan="1">&#x0003c;0.001<xref ref-type="fn" rid="jah31918-note-0007">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NT&#x02010;proBNP<sub>con LA (pg/mL) n=16</sub>
</td><td align="left" rowspan="1" colspan="1">94.3</td><td align="left" rowspan="1" colspan="1">59 to 150.8</td><td align="left" rowspan="1" colspan="1">92.9</td><td align="left" rowspan="1" colspan="1">58.8 to 146.9</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proANP<sub>int fv (pmol/L) n=29</sub>
</td><td align="left" rowspan="1" colspan="1">98.4</td><td align="left" rowspan="1" colspan="1">82.8 to 113.9</td><td align="left" rowspan="1" colspan="1">152</td><td align="left" rowspan="1" colspan="1">125.7 to 183.8</td><td align="left" rowspan="2" colspan="1">&#x0003c;0.001<xref ref-type="fn" rid="jah31918-note-0007">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proANP<sub>con fv (pmol/L) n=16</sub>
</td><td align="left" rowspan="1" colspan="1">102.7</td><td align="left" rowspan="1" colspan="1">77.9 to 151.3</td><td align="left" rowspan="1" colspan="1">108.3</td><td align="left" rowspan="1" colspan="1">85.2 to 137.8</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proANP<sub>int CS (pmol/L) n=26</sub>
</td><td align="left" rowspan="1" colspan="1">132.5</td><td align="left" rowspan="1" colspan="1">105.9 to 165.9</td><td align="left" rowspan="1" colspan="1">234.2</td><td align="left" rowspan="1" colspan="1">197.7 to 277.4</td><td align="left" rowspan="2" colspan="1">&#x0003c;0.001<xref ref-type="fn" rid="jah31918-note-0007">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proANP<sub>con CS (pmol/L) n=13</sub>
</td><td align="left" rowspan="1" colspan="1">151.5</td><td align="left" rowspan="1" colspan="1">116.1 to 197.8</td><td align="left" rowspan="1" colspan="1">161.7</td><td align="left" rowspan="1" colspan="1">123.2 to 213.6</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proANP<sub>int LA (pmol/L) n=29</sub>
</td><td align="left" rowspan="1" colspan="1">95.7</td><td align="left" rowspan="1" colspan="1">79.2 to 115.5</td><td align="left" rowspan="1" colspan="1">165.5</td><td align="left" rowspan="1" colspan="1">136.6 to 200.5</td><td align="left" rowspan="2" colspan="1">&#x0003c;0.001<xref ref-type="fn" rid="jah31918-note-0007">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proANP<sub>con LA (pmol/L) n=16</sub>
</td><td align="left" rowspan="1" colspan="1">100.9</td><td align="left" rowspan="1" colspan="1">79.5 to 128.1</td><td align="left" rowspan="1" colspan="1">106.2</td><td align="left" rowspan="1" colspan="1">82.7 to 136.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Copeptin<sub>int fv (pmol/L) n=29</sub>
</td><td align="left" rowspan="1" colspan="1">8.21</td><td align="left" rowspan="1" colspan="1">5.5 to 12.27</td><td align="left" rowspan="1" colspan="1">6.53</td><td align="left" rowspan="1" colspan="1">4.36 to 9.78</td><td align="left" rowspan="2" colspan="1">0.245</td></tr><tr><td align="left" rowspan="1" colspan="1">Copeptin<sub>con fv (pmol/L) n=16</sub>
</td><td align="left" rowspan="1" colspan="1">6.68</td><td align="left" rowspan="1" colspan="1">4.95 to 9.01</td><td align="left" rowspan="1" colspan="1">6.92</td><td align="left" rowspan="1" colspan="1">4.86 to 9.84</td></tr><tr><td align="left" rowspan="1" colspan="1">Copeptin<sub>int CS (pmol/L) n=26</sub>
</td><td align="left" rowspan="1" colspan="1">9.05</td><td align="left" rowspan="1" colspan="1">5.86 to 14</td><td align="left" rowspan="1" colspan="1">6.77</td><td align="left" rowspan="1" colspan="1">4.39 to 10.46</td><td align="left" rowspan="2" colspan="1">0.225</td></tr><tr><td align="left" rowspan="1" colspan="1">Copeptin<sub>con CS (pmol/L) n=13</sub>
</td><td align="left" rowspan="1" colspan="1">7.19</td><td align="left" rowspan="1" colspan="1">5.38 to 9.62</td><td align="left" rowspan="1" colspan="1">7.13</td><td align="left" rowspan="1" colspan="1">4.78 to 10.63</td></tr><tr><td align="left" rowspan="1" colspan="1">Copeptin<sub>int LA (pmol/L) n=29</sub>
</td><td align="left" rowspan="1" colspan="1">8.03</td><td align="left" rowspan="1" colspan="1">5.33 to 12.1</td><td align="left" rowspan="1" colspan="1">6.33</td><td align="left" rowspan="1" colspan="1">4.23 to 9.48</td><td align="left" rowspan="2" colspan="1">0.202</td></tr><tr><td align="left" rowspan="1" colspan="1">Copeptin<sub>con LA (pmol/L) n=16</sub>
</td><td align="left" rowspan="1" colspan="1">6.71</td><td align="left" rowspan="1" colspan="1">4.85 to 9.28</td><td align="left" rowspan="1" colspan="1">6.44</td><td align="left" rowspan="1" colspan="1">4.23 to 9.46</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proADM<sub>int fv (nmol/L) n=29</sub>
</td><td align="left" rowspan="1" colspan="1">0.583</td><td align="left" rowspan="1" colspan="1">0.53 to 0.636</td><td align="left" rowspan="1" colspan="1">0.568</td><td align="left" rowspan="1" colspan="1">0.522 to 0.614</td><td align="left" rowspan="2" colspan="1">0.363</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proADM<sub>con fv (nmol/L) n=16</sub>
</td><td align="left" rowspan="1" colspan="1">0.654</td><td align="left" rowspan="1" colspan="1">0.565 to 0.734</td><td align="left" rowspan="1" colspan="1">0.655</td><td align="left" rowspan="1" colspan="1">0.562 to 0.747</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proADM<sub>int CS (nmol/L) n=26</sub>
</td><td align="left" rowspan="1" colspan="1">0.563</td><td align="left" rowspan="1" colspan="1">0.513 to 0.613</td><td align="left" rowspan="1" colspan="1">0.558</td><td align="left" rowspan="1" colspan="1">0.507 to 0.61</td><td align="left" rowspan="2" colspan="1">0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proADM<sub>con CS (nmol/L) n=13</sub>
</td><td align="left" rowspan="1" colspan="1">0.636</td><td align="left" rowspan="1" colspan="1">0.547 to 0.724</td><td align="left" rowspan="1" colspan="1">0.628</td><td align="left" rowspan="1" colspan="1">0.528 to 0.728</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proADM<sub>int LA (nmol/L) n=29</sub>
</td><td align="left" rowspan="1" colspan="1">0.544</td><td align="left" rowspan="1" colspan="1">0.495 to 0.593</td><td align="left" rowspan="1" colspan="1">0.537</td><td align="left" rowspan="1" colspan="1">0.492 to 0.582</td><td align="left" rowspan="2" colspan="1">0.037</td></tr><tr><td align="left" rowspan="1" colspan="1">MR&#x02010;proADM<sub>con LA (nmol/L) n=16</sub>
</td><td align="left" rowspan="1" colspan="1">0.577</td><td align="left" rowspan="1" colspan="1">0.508 to 0.645</td><td align="left" rowspan="1" colspan="1">0.605</td><td align="left" rowspan="1" colspan="1">0.538 to 0.673</td></tr></tbody></table><table-wrap-foot><fn id="jah31918-note-0006"><p>NT&#x02010;proBNP, MR&#x02010;proANP, and copeptin levels are presented as geometric means with 95% CI; MR&#x02010;proADM levels are presented as means with 95% CI. Results from repeated&#x02010;measure ANOVA within&#x02010;subjects contrast tests are presented after correction for false discovery rates due to multiple testing. ANOVA indicates analysis of variance; CI, confidence interval; con, control group; CS, coronary sinus; fv, femoral vein; int, intervention group; LA, left atrium; MR&#x02010;proADM, midregional portion of proadrenomedullin; MR&#x02010;proANP, midregional fragment of the N&#x02010;terminal precursor of atrial natriuretic peptide; n, number of patients available for analysis; NT&#x02010;proBNP, N&#x02010;terminal pro B&#x02010;type natriuretic peptide.</p></fn><fn id="jah31918-note-0007"><label>a</label><p>Statistical significant <italic>P</italic> values after correction for false discovery rate.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="jah31918-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>
<styled-content style="fixed-case">MR</styled-content>&#x02010;pro<styled-content style="fixed-case">ANP</styled-content> reaction in randomized groups in fv, <styled-content style="fixed-case">CS</styled-content>, and <styled-content style="fixed-case">LA</styled-content>. <styled-content style="fixed-case">MR</styled-content>&#x02010;pro<styled-content style="fixed-case">ANP</styled-content> levels are presented as geometric means with 95% <styled-content style="fixed-case">CI</styled-content>. Results from repeated&#x02010;measure <styled-content style="fixed-case">ANOVA</styled-content> within&#x02010;subjects contrast tests between randomization groups based on interaction with time: <italic>P</italic>
<sub>time&#x000d7;randomization fv</sub>&#x0003c;0.001; <italic>P</italic>
<sub>time&#x000d7;randomization CS</sub>&#x0003c;0.001; <italic>P</italic>
<sub>time&#x000d7;randomization LA</sub>&#x0003c;0.001. <styled-content style="fixed-case">AF</styled-content> indicates atrial fibrillation; <styled-content style="fixed-case">ANOVA</styled-content>, analysis of variance; <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">CS</styled-content>, coronary sinus; fv, femoral vein; <styled-content style="fixed-case">LA</styled-content>, left atrium; <styled-content style="fixed-case">MR</styled-content>&#x02010;pro<styled-content style="fixed-case">ANP</styled-content>, mid&#x02010;regional fragment of the N&#x02010;terminal precursor of atrial natriuretic peptide; n, number of patients available for analyses.</p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-5-e003957-g002"/></fig></sec><sec id="jah31918-sec-0023"><title>NT&#x02010;proBNP</title><p>The AF initiation caused a significant increase in the NT&#x02010;proBNP concentration in LA after 30&#x000a0;minutes of AF compared with the baseline, but no significant change was observed in the NT&#x02010;proBNP concentrations in the control group in the same sampling locations. The NT&#x02010;proBNP reaction in the intervention group was statistically significant compared with the reaction in the control group in the same sampling site (<italic>P</italic>&#x0003c;0.001) (Figure&#x000a0;<xref rid="jah31918-fig-0003" ref-type="fig">3</xref> and Table&#x000a0;<xref rid="jah31918-tbl-0003" ref-type="table-wrap">3</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jah31918-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>
<styled-content style="fixed-case">NT</styled-content>&#x02010;pro<styled-content style="fixed-case">BNP</styled-content> reaction in randomized groups in <styled-content style="fixed-case">LA</styled-content>. <styled-content style="fixed-case">NT</styled-content>&#x02010;pro<styled-content style="fixed-case">BNP</styled-content> levels are presented as geometric means with 95% <styled-content style="fixed-case">CI</styled-content>. <italic>P</italic>
<sub>time&#x000d7;randomization</sub>&#x0003c;0.001 (from repeated&#x02010;measure <styled-content style="fixed-case">ANOVA</styled-content> within&#x02010;subjects contrast test between randomized groups based on interaction with time). <styled-content style="fixed-case">AF</styled-content> indicates atrial fibrillation; <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">LA</styled-content>, left atrium; n, number of patients available for analysis; <styled-content style="fixed-case">NT</styled-content>&#x02010;pro<styled-content style="fixed-case">BNP</styled-content>, N&#x02010;terminal pro&#x02010;B&#x02010;type natriuretic peptide.</p></caption><graphic id="nlm-graphic-5" xlink:href="JAH3-5-e003957-g003"/></fig><p>The reactions in NT&#x02010;proBNP concentrations in the femoral vein were not statistically different between the randomized groups (<italic>P</italic>=0.073; Table&#x000a0;<xref rid="jah31918-tbl-0003" ref-type="table-wrap">3</xref>). However, a marked increase in the NT&#x02010;proBNP concentration was observed in the intervention group directly at the end of RFA compared with the baseline in the femoral vein. On the other hand, the NT&#x02010;proBNP concentrations in the control group did not change significantly directly after the end of the RFA. The latter reaction in the intervention group was statistically significant when compared with the control group (<italic>P</italic>&#x0003c;0.001) (Table&#x000a0;<xref rid="jah31918-tbl-0004" ref-type="table-wrap">4</xref>, Figure&#x000a0;<xref rid="jah31918-fig-0004" ref-type="fig">4</xref>). The complication of pericardial effusion was entered as a covariate in this analysis without any significant impact on the result.</p><table-wrap id="jah31918-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>NT&#x02010;proBNP Reaction in Both Randomized Groups Directly After RFA Compared to Baseline</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Baseline</th><th align="left" valign="top" rowspan="1" colspan="1">95% CI</th><th align="left" valign="top" rowspan="1" colspan="1">Directly After RFA</th><th align="left" valign="top" rowspan="1" colspan="1">95% CI</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
<sub>time&#x000d7;randomization</sub>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NT&#x02010;proBNP<sub>int fv (pg/mL) n=29</sub>
</td><td align="left" rowspan="1" colspan="1">63.9</td><td align="left" rowspan="1" colspan="1">45.1 to 90.5</td><td align="left" rowspan="1" colspan="1">86.9</td><td align="left" rowspan="1" colspan="1">63 to 116.7</td><td align="left" rowspan="2" colspan="1">&#x0003c;0.001<xref ref-type="fn" rid="jah31918-note-0009">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NT&#x02010;proBNP<sub>con fv (pg/mL) n=16</sub>
</td><td align="left" rowspan="1" colspan="1">97.5</td><td align="left" rowspan="1" colspan="1">61.1 to 155.7</td><td align="left" rowspan="1" colspan="1">102.1</td><td align="left" rowspan="1" colspan="1">65.6 to 158.9</td></tr></tbody></table><table-wrap-foot><fn id="jah31918-note-0008"><p>NT&#x02010;proBNP levels are presented as geometric means with 95% CI. Results from repeated&#x02010;measure ANOVA within&#x02010;subjects contrast tests are presented and considered statistically significant after Benjamini&#x02010;Hochberg correction. ANOVA indicates analysis of variance; CI, confidence interval; con, control group; fv, femoral vein; int, intervention group; n, number of patients available for analysis; NT&#x02010;proBNP, N&#x02010;terminal pro B&#x02010;type natriuretic peptide.</p></fn><fn id="jah31918-note-0009"><label>a</label><p>Statistical significant <italic>P</italic> values after correction for false discovery rate.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="jah31918-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>
<styled-content style="fixed-case">NT</styled-content>&#x02010;pro<styled-content style="fixed-case">BNP</styled-content> reaction in randomization groups in femoral vein. <styled-content style="fixed-case">NT</styled-content>&#x02010;pro<styled-content style="fixed-case">BNP</styled-content> levels are presented as geometric means with 95% <styled-content style="fixed-case">CI</styled-content>. <italic>P</italic>
<sub>time&#x000d7;randomization</sub>&#x0003c;0.001 (from repeated&#x02010;measure <styled-content style="fixed-case">ANOVA</styled-content> within&#x02010;subjects contrast test between randomized groups based on interaction with time). <styled-content style="fixed-case">AF</styled-content> indicates atrial fibrillation; <styled-content style="fixed-case">CI</styled-content>, confidence interval; fv, femoral vein; group; n, number of patients available for analysis; <styled-content style="fixed-case">NT</styled-content>&#x02010;pro<styled-content style="fixed-case">BNP</styled-content>, N&#x02010;terminal pro&#x02010;B&#x02010;type natriuretic peptide.</p></caption><graphic id="nlm-graphic-7" xlink:href="JAH3-5-e003957-g004"/></fig><p>No differences in the NT&#x02010;proBNP reactions were observed between the randomized groups in the CS (<italic>P</italic>=0.882; Table&#x000a0;<xref rid="jah31918-tbl-0003" ref-type="table-wrap">3</xref>).</p></sec></sec><sec id="jah31918-sec-0024"><title>AF Initiation and Its Effect on Extracardiac Biomarkers</title><sec id="jah31918-sec-0025"><title>Copeptin</title><p>Copeptin concentrations did not change significantly 30&#x000a0;minutes after AF initiation compared with the control group (femoral vein <italic>P</italic>=0.245; CS <italic>P</italic>=0.225; LA <italic>P</italic>=0.202; Table&#x000a0;<xref rid="jah31918-tbl-0003" ref-type="table-wrap">3</xref>).</p><p>However, it was notable that the copeptin concentration after AF initiation in 2 patients with IHD included in the intervention group increased by 34.2 and 8.2&#x000a0;pmol/L, while that in the patient with IHD in the control group slightly decreased by 2&#x000a0;pmol/L in the femoral vein. Excluding these 3 patients from the analyses (n<sub>intervention</sub>=27; n<sub>controls</sub>=15), we observed that patients without IHD had decreased copeptin concentrations 30&#x000a0;minutes after AF initiation compared with the baseline, although the concentrations in the control group did not change. The copeptin reactions of the intervention group were statistically significant compared with the controls in the respective sampling sites (femoral vein <italic>P</italic>=0.003; CS <italic>P</italic>=0.015; LA <italic>P</italic>=0.011) (Table&#x000a0;<xref rid="jah31918-tbl-0005" ref-type="table-wrap">5</xref> and Figure&#x000a0;<xref rid="jah31918-fig-0005" ref-type="fig">5</xref>).</p><table-wrap id="jah31918-tbl-0005" xml:lang="en" orientation="portrait" position="float"><label>Table 5</label><caption><p>Copeptin Level Reactions in Patients Without IHD in fv, CS, and LA in Both Randomized Groups</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Baseline</th><th align="left" valign="top" rowspan="1" colspan="1">95% CI</th><th align="left" valign="top" rowspan="1" colspan="1">30&#x000a0;Minutes After the Induction</th><th align="left" valign="top" rowspan="1" colspan="1">95% CI</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
<sub>time&#x000d7;randomization</sub>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Copeptin<sub>int fv (pmol/L) n=27</sub>
</td><td align="left" rowspan="1" colspan="1">8.23</td><td align="left" rowspan="1" colspan="1">5.34 to 12.7</td><td align="left" rowspan="1" colspan="1">5.9</td><td align="left" rowspan="1" colspan="1">3.94 to 8.85</td><td align="left" rowspan="2" colspan="1">0.003<xref ref-type="fn" rid="jah31918-note-0011">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Copeptin<sub>con fv (pmol/L) n=15</sub>
</td><td align="left" rowspan="1" colspan="1">6.41</td><td align="left" rowspan="1" colspan="1">4.7 to 8.5</td><td align="left" rowspan="1" colspan="1">6.63</td><td align="left" rowspan="1" colspan="1">4.59 to 9.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Copeptin<sub>int CS (pmol/L) n=24</sub>
</td><td align="left" rowspan="1" colspan="1">9.04</td><td align="left" rowspan="1" colspan="1">5.64 to 14.5</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">3.94 to 9.1</td><td align="left" rowspan="2" colspan="1">0.015<xref ref-type="fn" rid="jah31918-note-0011">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Copeptin<sub>con CS (pmol/L) n=12</sub>
</td><td align="left" rowspan="1" colspan="1">6.79</td><td align="left" rowspan="1" colspan="1">5.1 to 9.04</td><td align="left" rowspan="1" colspan="1">6.78</td><td align="left" rowspan="1" colspan="1">4.45 to 10.35</td></tr><tr><td align="left" rowspan="1" colspan="1">Copeptin<sub>int LA (pmol/L) n=27</sub>
</td><td align="left" rowspan="1" colspan="1">7.93</td><td align="left" rowspan="1" colspan="1">5.1 to 12.35</td><td align="left" rowspan="1" colspan="1">5.67</td><td align="left" rowspan="1" colspan="1">3.84 to 8.37</td><td align="left" rowspan="2" colspan="1">0.011<xref ref-type="fn" rid="jah31918-note-0011">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Copeptin<sub>con LA (pmol/L) n=15</sub>
</td><td align="left" rowspan="1" colspan="1">6.37</td><td align="left" rowspan="1" colspan="1">4.59 to 8.83</td><td align="left" rowspan="1" colspan="1">6.18</td><td align="left" rowspan="1" colspan="1">4.31 to 8.86</td></tr></tbody></table><table-wrap-foot><fn id="jah31918-note-0010"><p>Copeptin levels are presented as geometric means with 95% CI. The results from repeated&#x02010;measure ANOVA within&#x02010;subjects&#x00227; contrast tests after correction for false discovery rates due to multiple testing. ANOVA indicates analysis of variance; CI, confidence intervals; con, control group; CS, coronary sinus; fv, femoral vein; IHD, ischemic heart disease; int, intervention group; LA, left atrium; n, number of patients available for analysis.</p></fn><fn id="jah31918-note-0011"><label>a</label><p>Statistical significant <italic>P</italic> values after correction for false discovery rate.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="jah31918-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Copeptin reaction in randomized groups in patients without <styled-content style="fixed-case">IHD</styled-content> in femoral vein, <styled-content style="fixed-case">CS</styled-content>, and <styled-content style="fixed-case">LA</styled-content>. Copeptin levels are presented as geometric means with 95% <styled-content style="fixed-case">CI</styled-content>. Results from repeated&#x02010;measure <styled-content style="fixed-case">ANOVA</styled-content> within&#x02010;subjects contrast tests between randomized groups based on interaction with time: <italic>P</italic>
<sub>time&#x000d7;randomization fv</sub>&#x0003c;0.003; <italic>P</italic>
<sub>time&#x000d7;randomization CS</sub>&#x0003c;0.015; <italic>P</italic>
<sub>time&#x000d7;randomization LA</sub>&#x0003c;0.011. <styled-content style="fixed-case">AF</styled-content> indicates atrial fibrillation; <styled-content style="fixed-case">ANOVA</styled-content>, analysis of variance; <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">CS</styled-content>, coronary sinus; fv, femoral vein; <styled-content style="fixed-case">IHD</styled-content>, ischemic heart disease; <styled-content style="fixed-case">LA</styled-content>, left atrium; n, number of patients available for analysis.</p></caption><graphic id="nlm-graphic-9" xlink:href="JAH3-5-e003957-g005"/></fig></sec><sec id="jah31918-sec-0026"><title>MR&#x02010;proADM</title><p>The MR&#x02010;proADM reactions did not differ significantly between the randomized groups in different sites after correction for false discovery due to multiple testing (femoral vein <italic>P</italic>=0.363; CS <italic>P</italic>=0.610; LA <italic>P</italic>=0.037; Table&#x000a0;<xref rid="jah31918-tbl-0003" ref-type="table-wrap">3</xref>).</p></sec></sec></sec><sec id="jah31918-sec-0027"><title>Discussion</title><p>In this study we examined the effects of induced AF lasting for at least 30&#x000a0;minutes on 2 biomarkers with cardiac origin (NT&#x02010;proBNP and MR&#x02010;proANP) and 2 biomarkers with extracardiac origin (copeptin and MR&#x02010;proADM). This is the first study to show that 30&#x000a0;minutes of AF resulted in an increase in the cardiac biomarker concentrations. Therefore, these findings allow us to better understand the pathophysiology behind AF.</p><sec id="jah31918-sec-0028"><title>AF Initiation and Its Effect on Cardiac Biomarkers</title><sec id="jah31918-sec-0029"><title>MR&#x02010;proANP</title><p>Interestingly, we observed an immediate increase in the MR&#x02010;proANP concentrations in all sampling sites after the initiation of AF. The proANP is stored in secretory granules in the atrial myocytes and splits into ANP and NT&#x02010;proANP fragments on secretion in response to increased wall tension.<xref rid="jah31918-bib-0026" ref-type="ref">26</xref> A previous study has shown that the MR&#x02010;proANP concentration was elevated in patients with AF but without HF, compared with controls. It also showed that the MR&#x02010;proANP concentration increased during the initial days to weeks of AF initiation and then gradually decreased when AF persisted.<xref rid="jah31918-bib-0008" ref-type="ref">8</xref> The increased atrial wall tension and volume overload were believed to be the key stimuli for the secretion of natriuretic peptides.<xref rid="jah31918-bib-0027" ref-type="ref">27</xref>, <xref rid="jah31918-bib-0028" ref-type="ref">28</xref>, <xref rid="jah31918-bib-0029" ref-type="ref">29</xref> Another recent study proposed the high&#x02010;frequency contraction of atrial myocytes resulting in a local inflammation as a possible additional stimulus in patients with persistent AF.<xref rid="jah31918-bib-0030" ref-type="ref">30</xref> Furthermore, the immediate increase in MR&#x02010;proANP observed in our study can be explained by the fact that ANP releases as rapidly as 2&#x000a0;minutes from the application of the stimulus.<xref rid="jah31918-bib-0031" ref-type="ref">31</xref>
</p></sec><sec id="jah31918-sec-0030"><title>NT&#x02010;proBNP</title><p>Our results demonstrated a minor but significant increase in NT&#x02010;proBNP concentration in LA 30&#x000a0;minutes after initiation of AF and an increase in NT&#x02010;proBNP level in femoral vein directly after the RFA, compared with the baseline. The NT&#x02010;proBNP concentration increases in plasma in patients with so&#x02010;called &#x0201c;lone AF&#x0201d;<xref rid="jah31918-bib-0005" ref-type="ref">5</xref> (AF without cardiac comorbidity), possibly due to the increased atrial wall tension and possible atrial inflammation.<xref rid="jah31918-bib-0003" ref-type="ref">3</xref> Consequently the restoration of sinus rhythm decreases the plasma BNP concentration.<xref rid="jah31918-bib-0032" ref-type="ref">32</xref> A study by Suzuki et&#x000a0;al<xref rid="jah31918-bib-0033" ref-type="ref">33</xref> on cultured rat atrial cells showed that BNP is secreted directly after synthesis; however, some synthesized BNP may be stored in a small subset of atrial granules. Goetze et&#x000a0;al argued that the BNP precursor is also stored in the atrial granule.<xref rid="jah31918-bib-0003" ref-type="ref">3</xref> From these data, it could be inferred that the modest increase in NT&#x02010;proBNP concentration 30&#x000a0;minutes after the initiation of AF could be attributed to the limited amount of NT&#x02010;proBNP that is stored in granules and could thus be directly released after the initiation of AF.</p><p>The marked increase, compared with controls, observed in peripheral blood directly after RFA should be discussed. The major stimulus is probably the increased wall tension due to the hemodynamic changes during AF but may also be due to the increased volume as a result of the volume given during the RFA. The RFA process itself could be a factor behind the increase in NT&#x02010;proBNP due to myocardial injury and volume overload,<xref rid="jah31918-bib-0034" ref-type="ref">34</xref>, <xref rid="jah31918-bib-0035" ref-type="ref">35</xref>, <xref rid="jah31918-bib-0036" ref-type="ref">36</xref> but this effect is equal in both study groups, as all patients underwent RFA. Thus, this could not explain the different reactions between the randomized groups.</p><p>Furthermore, Inoue et&#x000a0;al<xref rid="jah31918-bib-0037" ref-type="ref">37</xref> have suggested that BNP is secreted mostly from atrial cells in patients with AF, which can probably explain why we found an isolated and significant increase of NT&#x02010;proBNP levels in LA 30&#x000a0;minutes after AF initiation but no significant changes in NT&#x02010;proBNP levels in CS and peripheral blood.</p></sec></sec><sec id="jah31918-sec-0031"><title>AF Initiation and Its Effect on Extracardiac Biomarkers</title><p>Interestingly, the copeptin levels in patients without IHD were decreased after the initiation of AF.</p><p>Copeptin and AVP are produced in the hypothalamus and released from the neurohypophysis in response to a drop in blood pressure, changes in osmotic pressure, and endogenous stress (eg, acute MI).<xref rid="jah31918-bib-0038" ref-type="ref">38</xref> The physiological relevance of copeptin is unknown, but AVP can lead to the release of adrenocorticotropic hormone (ACTH), water retention, and vasoconstriction as part of the volume regulation in which AVP has a major role.<xref rid="jah31918-bib-0038" ref-type="ref">38</xref>
</p><p>In our study we found an increase in the diastolic blood pressure (DBP) by 7&#x000a0;mm&#x000a0;Hg after 30&#x000a0;minutes of AF in the intervention group. This reaction was significantly different from that of the control group (Figure&#x000a0;<xref rid="jah31918-fig-0006" ref-type="fig">6</xref>). The increase in DBP as a result of AF was also confirmed in a previous study.<xref rid="jah31918-bib-0039" ref-type="ref">39</xref> Thus, it can be assumed that the decrease in copeptin concentration after the initiation of AF can be attributed to the increase in DBP.<xref rid="jah31918-bib-0038" ref-type="ref">38</xref>, <xref rid="jah31918-bib-0040" ref-type="ref">40</xref> It is also well known that the copeptin concentration increases following an acute MI,<xref rid="jah31918-bib-0009" ref-type="ref">9</xref> and the increase in copeptin in the 2 patients with IHD could possibly be attributed to ischemia following elevated heart rate.</p><fig fig-type="Figure" xml:lang="en" id="jah31918-fig-0006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>
<styled-content style="fixed-case">DBP</styled-content> reaction in both randomized groups. <styled-content style="fixed-case">AF</styled-content> indicates atrial fibrillation; <styled-content style="fixed-case">DBP</styled-content>, diastolic blood pressure; n, number of patients available for analysis.</p></caption><graphic id="nlm-graphic-11" xlink:href="JAH3-5-e003957-g006"/></fig><p>The reaction on MR&#x02010;proADM concentration after AF induction did not differ between the randomized groups after adjustment for false discovery rate. Considering the increased shear stress and inflammation due to AF initiation, an increase of MR&#x02010;proADM levels could have been expected, which our results failed to show.</p></sec><sec id="jah31918-sec-0032"><title>Clinical and Investigational Importance and Future Perspectives</title><p>To the best of our knowledge this is the first randomized study with a control arm showing the association of novel biomarkers following 30&#x000a0;minutes of induced atrial fibrillation.</p><p>Our study showed that MR&#x02010;proANP levels increased in all blood sampling sites 30&#x000a0;minutes after AF initiation. A previous study by Meune et&#x000a0;al has shown that the MR&#x02010;proANP level correlated with the duration of AF episodes.<xref rid="jah31918-bib-0008" ref-type="ref">8</xref> Thus, MR&#x02010;proANP can be used as a biomarker of AF. New studies are needed in order to verify if MR&#x02010;proANP can serve as an indicator for AF duration &#x0003c;48&#x000a0;hours and thus identify candidates for cardioversion without the otherwise mandatory pretreatment with anticoagulants.</p><p>Another interesting finding was the increase in NT&#x02010;proBNP in LA 30&#x000a0;minutes after the initiation of AF, and in peripheral blood at the end of the RFA procedure. More studies are needed in order to find out whether the increase of the NT&#x02010;proBNP levels is due to a direct release from the LA myocardial granules or the result of an early production. Furthermore, the early increase of MR&#x02010;proANP and NT&#x02010;proBNP is of potential clinical importance because it shows that both natriuretic peptides can serve as biomarkers of the initiation/start of AF.</p><p>One interesting observation was the decrease in copeptin in all patients apart from those 2 with IHD. In those 2 patients an increase in copeptin was observed instead. As this was only an observation, more studies are needed in order to confirm it.</p></sec><sec id="jah31918-sec-0033"><title>Limitations</title><p>Our study was a single&#x02010;center randomized study with a moderate sample size. Our sample consisted of a relatively healthy group of patients with few comorbidities, and the extrapolation of our results to a general population with AF has to be done with caution. Moreover, the initiation of AF by burst pacing is a simulation model of the real pathophysiological mechanism. Examining the levels of these biomarkers 1 or 2&#x000a0;hours after the AF initiation could have provided us with better knowledge of their reactions, but this was considered unethical and unsafe. Finally, performing sample collection post&#x02010;RFA in CS or LA could have provided more information but was not included in the protocol due to the further increase in procedure time and the addition of a new intervention (new catheterization of CS), which would have increased the risk of complications.</p></sec></sec><sec id="jah31918-sec-0034"><title>Conclusions</title><p>AF is a strong stimulus that causes an immediate activation of different biomarkers and has an immediate effect on hemodynamics. The NT&#x02010;proBNP and MR&#x02010;proANP concentrations increased after the initiation of AF, whereas the copeptin level decreased in patients without IHD; however, no significant changes were detected in the MR&#x02010;proADM concentration. This is the first study to examine the results of both cardiac and extracardiac biomarkers immediately after AF initiation. More research regarding the mechanisms affecting the balance of these biomarkers and their effects is needed in order to better evaluate the results.</p></sec><sec id="jah31918-sec-0035"><title>Sources of Funding</title><p>The SMURF study is supported by grants from ALF&#x02010;grants (agreement on medical training and research grants between County Council of &#x000d6;sterg&#x000f6;tland and Link&#x000f6;ping University), the Carldavid J&#x000f6;nsson Research Foundation, the Heart Foundation, Link&#x000f6;ping University<bold>,</bold> and by unrestricted grants from Biosense Webster and Johnson &#x00026; Johnson.</p></sec><sec id="jah31918-sec-0036"><title>Disclosures</title><p>None.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><caption><p>
<bold>Table&#x000a0;S1.</bold> Baseline Characteristics of Patients Included in the Analyses of Biomarkers in CS and Those We Were Unable to Catheterize CS</p></caption><media xlink:href="JAH3-5-e003957-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="jah31918-bibl-0001"><title>References</title><ref id="jah31918-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah31918-cit-0001">
<string-name>
<surname>Friberg</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Bergfeldt</surname>
<given-names>L</given-names>
</string-name>. <article-title>Atrial fibrillation prevalence revisited</article-title>. <source>J Intern Med</source>. <year>2013</year>;<volume>274</volume>:<fpage>461</fpage>&#x02013;<lpage>468</lpage>.<pub-id pub-id-type="pmid">23879838</pub-id></mixed-citation></ref><ref id="jah31918-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah31918-cit-0002">
<string-name>
<surname>Hijazi</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Oldgren</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Siegbahn</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</string-name>. <article-title>Biomarkers in atrial fibrillation: a clinical review</article-title>. <source>Eur Heart J</source>. <year>2013</year>;<volume>34</volume>:<fpage>1475</fpage>&#x02013;<lpage>1480</lpage>.<pub-id pub-id-type="pmid">23386711</pub-id></mixed-citation></ref><ref id="jah31918-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah31918-cit-0003">
<string-name>
<surname>Goetze</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Friis&#x02010;Hansen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Rehfeld</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Nilsson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Svendsen</surname>
<given-names>JH</given-names>
</string-name>. <article-title>Atrial secretion of B&#x02010;type natriuretic peptide</article-title>. <source>Eur Heart J</source>. <year>2006</year>;<volume>27</volume>:<fpage>1648</fpage>&#x02013;<lpage>1650</lpage>.<pub-id pub-id-type="pmid">16785247</pub-id></mixed-citation></ref><ref id="jah31918-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah31918-cit-0004">
<string-name>
<surname>Yasue</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yoshimura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sumida</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kikuta</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kugiyama</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Jougasaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ogawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Okumura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mukoyama</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nakao</surname>
<given-names>K</given-names>
</string-name>. <article-title>Localization and mechanism of secretion of B&#x02010;type natriuretic peptide in comparison with those of A&#x02010;type natriuretic peptide in normal subjects and patients with heart failure</article-title>. <source>Circulation</source>. <year>1994</year>;<volume>90</volume>:<fpage>195</fpage>&#x02013;<lpage>203</lpage>.<pub-id pub-id-type="pmid">8025996</pub-id></mixed-citation></ref><ref id="jah31918-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah31918-cit-0005">
<string-name>
<surname>Ellinor</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Low</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Patton</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Shea</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Macrae</surname>
<given-names>CA</given-names>
</string-name>. <article-title>Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation</article-title>. <source>J Am Coll Cardiol</source>. <year>2005</year>;<volume>45</volume>:<fpage>82</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">15629379</pub-id></mixed-citation></ref><ref id="jah31918-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah31918-cit-0006">
<string-name>
<surname>Patton</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Ellinor</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Heckbert</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Christenson</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>DeFilippi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gottdiener</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Kronmal</surname>
<given-names>RA</given-names>
</string-name>. <article-title>N&#x02010;Terminal pro&#x02010;B&#x02010;type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>120</volume>:<fpage>1768</fpage>&#x02013;<lpage>1774</lpage>.<pub-id pub-id-type="pmid">19841297</pub-id></mixed-citation></ref><ref id="jah31918-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah31918-cit-0007">
<string-name>
<surname>Morgenthaler</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Struck</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Bergmann</surname>
<given-names>A</given-names>
</string-name>. <article-title>Immunoluminometric assay for the midregion of pro&#x02010;atrial natriuretic peptide in human plasma</article-title>. <source>Clin Chem</source>. <year>2004</year>;<volume>50</volume>:<fpage>234</fpage>&#x02013;<lpage>236</lpage>.<pub-id pub-id-type="pmid">14709661</pub-id></mixed-citation></ref><ref id="jah31918-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah31918-cit-0008">
<string-name>
<surname>Meune</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Vermillet</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wahbi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Guerin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Aelion</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Weber</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chenevier&#x02010;Gobeaux</surname>
<given-names>C</given-names>
</string-name>. <article-title>Mid&#x02010;regional pro atrial natriuretic peptide allows the accurate identification of patients with atrial fibrillation of short time of onset: a pilot study</article-title>. <source>Clin Biochem</source>. <year>2011</year>;<volume>44</volume>:<fpage>1315</fpage>&#x02013;<lpage>1319</lpage>.<pub-id pub-id-type="pmid">21871875</pub-id></mixed-citation></ref><ref id="jah31918-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah31918-cit-0009">
<string-name>
<surname>Voors</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>von Haehling</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Anker</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Hillege</surname>
<given-names>HL</given-names>
</string-name>, <string-name>
<surname>Struck</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hartmann</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Bergmann</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Squire</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>van Veldhuisen</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Dickstein</surname>
<given-names>K</given-names>
</string-name>; <collab collab-type="authors">OPTIMAAL Investigators</collab>
. <article-title>C&#x02010;terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study</article-title>. <source>Eur Heart J</source>. <year>2009</year>;<volume>30</volume>:<fpage>1187</fpage>&#x02013;<lpage>1194</lpage>.<pub-id pub-id-type="pmid">19346228</pub-id></mixed-citation></ref><ref id="jah31918-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah31918-cit-0010">
<string-name>
<surname>Chatterjee</surname>
<given-names>K</given-names>
</string-name>. <article-title>Neurohormonal activation in congestive heart failure and the role of vasopressin</article-title>. <source>Am J Cardiol</source>. <year>2005</year>;<volume>95</volume>:<fpage>8B</fpage>&#x02013;<lpage>13B</lpage>.<pub-id pub-id-type="pmid">15619386</pub-id></mixed-citation></ref><ref id="jah31918-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah31918-cit-0011">
<string-name>
<surname>Morgenthaler</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Struck</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Alonso</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bergmann</surname>
<given-names>A</given-names>
</string-name>. <article-title>Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin</article-title>. <source>Clin Chem</source>. <year>2006</year>;<volume>52</volume>:<fpage>112</fpage>&#x02013;<lpage>119</lpage>.<pub-id pub-id-type="pmid">16269513</pub-id></mixed-citation></ref><ref id="jah31918-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah31918-cit-0012">
<string-name>
<surname>Alehagen</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Dahlstrom</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Rehfeld</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Goetze</surname>
<given-names>JP</given-names>
</string-name>. <article-title>Association of copeptin and N&#x02010;terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure</article-title>. <source>JAMA</source>. <year>2011</year>;<volume>305</volume>:<fpage>2088</fpage>&#x02013;<lpage>2095</lpage>.<pub-id pub-id-type="pmid">21610241</pub-id></mixed-citation></ref><ref id="jah31918-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah31918-cit-0013">
<string-name>
<surname>Roffi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Patrono</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Collet</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Mueller</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Valgimigli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Andreotti</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Bax</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Borger</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Brotons</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chew</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Gencer</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Hasenfuss</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kjeldsen</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Lancellotti</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Landmesser</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Mehilli</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mukherjee</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Storey</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Windecker</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Baumgartner</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Gaemperli</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Achenbach</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Agewall</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Badimon</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Baigent</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bueno</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Bugiardini</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Carerj</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Casselman</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Cuisset</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Erol</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fitzsimons</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Halle</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hamm</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hildick&#x02010;Smith</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Huber</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Iliodromitis</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>James</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Lip</surname>
<given-names>GY</given-names>
</string-name>, <string-name>
<surname>Piepoli</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Richter</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Rosemann</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sechtem</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Steg</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Vrints</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Luis Zamorano</surname>
<given-names>J</given-names>
</string-name>; <collab collab-type="authors">Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST&#x02010;Segment Elevation of the European Society of Cardiology</collab>
. <article-title>2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST&#x02010;segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST&#x02010;Segment Elevation of the European Society of Cardiology (ESC)</article-title>. <source>Eur Heart J</source>. <year>2016</year>;<volume>37</volume>:<fpage>267</fpage>&#x02013;<lpage>315</lpage>.<pub-id pub-id-type="pmid">26320110</pub-id></mixed-citation></ref><ref id="jah31918-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah31918-cit-0014">
<string-name>
<surname>Sabatine</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Morrow</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>de Lemos</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Omland</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sloan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jarolim</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Solomon</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Pfeffer</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Braunwald</surname>
<given-names>E</given-names>
</string-name>. <article-title>Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease</article-title>. <source>Circulation</source>. <year>2012</year>;<volume>125</volume>:<fpage>233</fpage>&#x02013;<lpage>240</lpage>.<pub-id pub-id-type="pmid">22179538</pub-id></mixed-citation></ref><ref id="jah31918-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah31918-cit-0015">
<string-name>
<surname>Jougasaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Burnett</surname>
<given-names>JC</given-names>
<suffix>Jr</suffix>
</string-name>. <article-title>Adrenomedullin: potential in physiology and pathophysiology</article-title>. <source>Life Sci</source>. <year>2000</year>;<volume>66</volume>:<fpage>855</fpage>&#x02013;<lpage>872</lpage>.<pub-id pub-id-type="pmid">10714887</pub-id></mixed-citation></ref><ref id="jah31918-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah31918-cit-0016">
<string-name>
<surname>Sugo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Minamino</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kangawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Miyamoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kitamura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sakata</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Eto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Matsuo</surname>
<given-names>H</given-names>
</string-name>. <article-title>Endothelial cells actively synthesize and secrete adrenomedullin</article-title>. <source>Biochem Biophys Res Commun</source>. <year>1994</year>;<volume>201</volume>:<fpage>1160</fpage>&#x02013;<lpage>1166</lpage>.<pub-id pub-id-type="pmid">8024557</pub-id></mixed-citation></ref><ref id="jah31918-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah31918-cit-0017">
<string-name>
<surname>Sugo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Minamino</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Shoji</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kangawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kitamura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Eto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Matsuo</surname>
<given-names>H</given-names>
</string-name>. <article-title>Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor&#x02010;alpha</article-title>. <source>Biochem Biophys Res Commun</source>. <year>1994</year>;<volume>203</volume>:<fpage>719</fpage>&#x02013;<lpage>726</lpage>.<pub-id pub-id-type="pmid">8074727</pub-id></mixed-citation></ref><ref id="jah31918-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah31918-cit-0018">
<string-name>
<surname>Chun</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Itoh</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ogawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tamura</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Takaya</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Igaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yamashita</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Doi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Inoue</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Masatsugu</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Korenaga</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ando</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Nakao</surname>
<given-names>K</given-names>
</string-name>. <article-title>Shear stress augments expression of C&#x02010;type natriuretic peptide and adrenomedullin</article-title>. <source>Hypertension</source>. <year>1997</year>;<volume>29</volume>:<fpage>1296</fpage>&#x02013;<lpage>1302</lpage>.<pub-id pub-id-type="pmid">9180632</pub-id></mixed-citation></ref><ref id="jah31918-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah31918-cit-0019">
<string-name>
<surname>Morgenthaler</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Struck</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Alonso</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bergmann</surname>
<given-names>A</given-names>
</string-name>. <article-title>Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay</article-title>. <source>Clin Chem</source>. <year>2005</year>;<volume>51</volume>:<fpage>1823</fpage>&#x02013;<lpage>1829</lpage>.<pub-id pub-id-type="pmid">16099941</pub-id></mixed-citation></ref><ref id="jah31918-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah31918-cit-0020">
<string-name>
<surname>Parwani</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>von Haehling</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kolodziejski</surname>
<given-names>AI</given-names>
</string-name>, <string-name>
<surname>Huemer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wutzler</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Attanasio</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Stojakovic</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Scharnagl</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Haverkamp</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Boldt</surname>
<given-names>LH</given-names>
</string-name>. <article-title>Mid&#x02010;regional proadrenomedullin levels predict recurrence of atrial fibrillation after catheter ablation</article-title>. <source>Int J Cardiol</source>. <year>2015</year>;<volume>180</volume>:<fpage>129</fpage>&#x02013;<lpage>133</lpage>.<pub-id pub-id-type="pmid">25438233</pub-id></mixed-citation></ref><ref id="jah31918-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah31918-cit-0021">
<string-name>
<surname>Charitakis</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Walfridsson</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Nystrom</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Nylander</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Stromberg</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Alehagen</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Walfridsson</surname>
<given-names>H</given-names>
</string-name>. <article-title>Symptom burden, Metabolic profile, Ultrasound findings, Rhythm, neurohormonal activation, haemodynamics and health&#x02010;related quality of life in patients with atrial Fibrillation (SMURF): a protocol for an observational study with a randomised interventional component</article-title>. <source>BMJ Open</source>. <year>2015</year>;<volume>5</volume>:<fpage>e008723</fpage>.</mixed-citation></ref><ref id="jah31918-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah31918-cit-0022">
<string-name>
<surname>Rickham</surname>
<given-names>PP</given-names>
</string-name>. <article-title>Human experimentation. Code of ethics of the World Medical Association. Declaration of Helsinki</article-title>. <source>Br Med J</source>. <year>1964</year>;<volume>2</volume>:<fpage>177</fpage>.<pub-id pub-id-type="pmid">14150898</pub-id></mixed-citation></ref><ref id="jah31918-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah31918-cit-0023">
<string-name>
<surname>Hendrikx</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Rosenqvist</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wester</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sandstrom</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hornsten</surname>
<given-names>R</given-names>
</string-name>. <article-title>Intermittent short ECG recording is more effective than 24&#x02010;hour Holter ECG in detection of arrhythmias</article-title>. <source>BMC Cardiovasc Disord</source>. <year>2014</year>;<volume>14</volume>:<fpage>41</fpage>.<pub-id pub-id-type="pmid">24690488</pub-id></mixed-citation></ref><ref id="jah31918-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah31918-cit-0024">
<string-name>
<surname>Doliwa Sobocinski</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Anggardh Rooth</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Frykman Kull</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>von Arbin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wallen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Rosenqvist</surname>
<given-names>M</given-names>
</string-name>. <article-title>Improved screening for silent atrial fibrillation after ischaemic stroke</article-title>. <source>Europace</source>. <year>2012</year>;<volume>14</volume>:<fpage>1112</fpage>&#x02013;<lpage>1116</lpage>.<pub-id pub-id-type="pmid">22308086</pub-id></mixed-citation></ref><ref id="jah31918-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah31918-cit-0025">
<string-name>
<surname>Benjamini</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hochberg</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Controlling the false discovery rate&#x02014;a practical and powerful approach to multiple testing</article-title>. <source>J Roy Stat Soc Ser B Methodol</source>. <year>1995</year>;<volume>57</volume>:<fpage>289</fpage>&#x02013;<lpage>300</lpage>.</mixed-citation></ref><ref id="jah31918-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah31918-cit-0026">
<string-name>
<surname>Mukoyama</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nakao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hosoda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Suga</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ogawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shirakami</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Jougasaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Obata</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yasue</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kambayashi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Inouye</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Imura</surname>
<given-names>H</given-names>
</string-name>. <article-title>Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide</article-title>. <source>J Clin Invest</source>. <year>1991</year>;<volume>87</volume>:<fpage>1402</fpage>&#x02013;<lpage>1412</lpage>.<pub-id pub-id-type="pmid">1849149</pub-id></mixed-citation></ref><ref id="jah31918-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah31918-cit-0027">
<string-name>
<surname>Levin</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Gardner</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Samson</surname>
<given-names>WK</given-names>
</string-name>. <article-title>Natriuretic peptides</article-title>. <source>N Engl J Med</source>. <year>1998</year>;<volume>339</volume>:<fpage>321</fpage>&#x02013;<lpage>328</lpage>.<pub-id pub-id-type="pmid">9682046</pub-id></mixed-citation></ref><ref id="jah31918-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jah31918-cit-0028">
<string-name>
<surname>Edwards</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Zimmerman</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Schwab</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Heublein</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Burnett</surname>
<given-names>JC</given-names>
<suffix>Jr</suffix>
</string-name>. <article-title>Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor</article-title>. <source>Circ Res</source>. <year>1988</year>;<volume>62</volume>:<fpage>191</fpage>&#x02013;<lpage>195</lpage>.<pub-id pub-id-type="pmid">2962782</pub-id></mixed-citation></ref><ref id="jah31918-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jah31918-cit-0029">
<string-name>
<surname>Brookes</surname>
<given-names>CI</given-names>
</string-name>, <string-name>
<surname>Kemp</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Hooper</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Oldershaw</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Moat</surname>
<given-names>NE</given-names>
</string-name>. <article-title>Plasma brain natriuretic peptide concentrations in patients with chronic mitral regurgitation</article-title>. <source>J Heart Valve Dis</source>. <year>1997</year>;<volume>6</volume>:<fpage>608</fpage>&#x02013;<lpage>612</lpage>.<pub-id pub-id-type="pmid">9427129</pub-id></mixed-citation></ref><ref id="jah31918-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jah31918-cit-0030">
<string-name>
<surname>Mollmann</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Weber</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Elsasser</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nef</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Dill</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Rixe</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Schmitt</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sperzel</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hamm</surname>
<given-names>CW</given-names>
</string-name>. <article-title>NT&#x02010;ProBNP predicts rhythm stability after cardioversion of lone atrial fibrillation</article-title>. <source>Circ J</source>. <year>2008</year>;<volume>72</volume>:<fpage>921</fpage>&#x02013;<lpage>925</lpage>.<pub-id pub-id-type="pmid">18503217</pub-id></mixed-citation></ref><ref id="jah31918-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jah31918-cit-0031">
<string-name>
<surname>Lindberg</surname>
<given-names>BF</given-names>
</string-name>, <string-name>
<surname>Hambraeus</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Wollmer</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Andersson</surname>
<given-names>KE</given-names>
</string-name>. <article-title>Release of atrial natriuretic peptide during pulmonary artery clamping in man</article-title>. <source>Clin Physiol</source>. <year>1997</year>;<volume>17</volume>:<fpage>449</fpage>&#x02013;<lpage>458</lpage>.<pub-id pub-id-type="pmid">9347194</pub-id></mixed-citation></ref><ref id="jah31918-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jah31918-cit-0032">
<string-name>
<surname>Wozakowska&#x02010;Kaplon</surname>
<given-names>B</given-names>
</string-name>. <article-title>Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation</article-title>. <source>Am J Cardiol</source>. <year>2004</year>;<volume>93</volume>:<fpage>1555</fpage>&#x02013;<lpage>1558</lpage>.<pub-id pub-id-type="pmid">15194036</pub-id></mixed-citation></ref><ref id="jah31918-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jah31918-cit-0033">
<string-name>
<surname>Suzuki</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hirata</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kohmoto</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Sugimoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hayakawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Matsuoka</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sugimoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kojima</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kangawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Minamino</surname>
<given-names>N</given-names>
</string-name>. <article-title>Cellular mechanisms for&#x000a0;synthesis and secretion of atrial natriuretic peptide and brain natriuretic&#x000a0;peptide in cultured rat atrial cells</article-title>. <source>Circ Res</source>. <year>1992</year>;<volume>71</volume>:<fpage>1039</fpage>&#x02013;<lpage>1048</lpage>.<pub-id pub-id-type="pmid">1394868</pub-id></mixed-citation></ref><ref id="jah31918-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jah31918-cit-0034">
<string-name>
<surname>Chen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>. <article-title>Effect of radiofrequency catheter ablation on plasma B&#x02010;type natriuretic peptide</article-title>. <source>Pacing Clin Electrophysiol</source>. <year>2005</year>;<volume>28</volume>:<fpage>200</fpage>&#x02013;<lpage>204</lpage>.<pub-id pub-id-type="pmid">15733179</pub-id></mixed-citation></ref><ref id="jah31918-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jah31918-cit-0035">
<string-name>
<surname>Seiler</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Steven</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Roberts&#x02010;Thomson</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Inada</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tedrow</surname>
<given-names>UB</given-names>
</string-name>, <string-name>
<surname>Michaud</surname>
<given-names>GF</given-names>
</string-name>, <string-name>
<surname>Stevenson</surname>
<given-names>WG</given-names>
</string-name>. <article-title>The effect of open&#x02010;irrigated radiofrequency catheter ablation of atrial fibrillation on left atrial pressure and B&#x02010;type natriuretic peptide</article-title>. <source>Pacing Clin Electrophysiol</source>. <year>2014</year>;<volume>37</volume>:<fpage>616</fpage>&#x02013;<lpage>623</lpage>.<pub-id pub-id-type="pmid">24372302</pub-id></mixed-citation></ref><ref id="jah31918-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jah31918-cit-0036">
<string-name>
<surname>Charitakis</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Walfridsson</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Alehagen</surname>
<given-names>U</given-names>
</string-name>. <article-title>Short&#x02010;term influence of radiofrequency ablation on NT&#x02010;proBNP, MR&#x02010;proANP, copeptin, and MR&#x02010;proADM in patients with atrial fibrillation: data from the observational SMURF study</article-title>. <source>J Am Heart Assoc</source>. <year>2016</year>;<volume>5</volume>:<fpage>e003557</fpage> doi: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.116.003557">10.1161/JAHA.116.003557</ext-link>.<pub-id pub-id-type="pmid">27633393</pub-id></mixed-citation></ref><ref id="jah31918-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jah31918-cit-0037">
<string-name>
<surname>Inoue</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Murakami</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Sano</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Katoh</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Shimada</surname>
<given-names>T</given-names>
</string-name>. <article-title>Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation</article-title>. <source>J Card Fail</source>. <year>2000</year>;<volume>6</volume>:<fpage>92</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">10908082</pub-id></mixed-citation></ref><ref id="jah31918-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jah31918-cit-0038">
<string-name>
<surname>Morgenthaler</surname>
<given-names>NG</given-names>
</string-name>. <article-title>Copeptin: a biomarker of cardiovascular and renal function</article-title>. <source>Congest Heart Fail</source>. <year>2010</year>;<volume>16</volume>(<issue>suppl 1</issue>):<fpage>S37</fpage>&#x02013;<lpage>S44</lpage>.<pub-id pub-id-type="pmid">20653710</pub-id></mixed-citation></ref><ref id="jah31918-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jah31918-cit-0039">
<string-name>
<surname>Alboni</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Scarfo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fuca</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Paparella</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yannacopulu</surname>
<given-names>P</given-names>
</string-name>. <article-title>Hemodynamics of idiopathic paroxysmal atrial fibrillation</article-title>. <source>Pacing Clin Electrophysiol</source>. <year>1995</year>;<volume>18</volume>:<fpage>980</fpage>&#x02013;<lpage>985</lpage>.<pub-id pub-id-type="pmid">7659571</pub-id></mixed-citation></ref><ref id="jah31918-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jah31918-cit-0040">
<string-name>
<surname>Morgenthaler</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Struck</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bergmann</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Redl</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Christ&#x02010;Crain</surname>
<given-names>M</given-names>
</string-name>. <article-title>Copeptin, a stable peptide of the arginine vasopressin precursor, is&#x000a0;elevated in hemorrhagic and septic shock</article-title>. <source>Shock</source>. <year>2007</year>;<volume>28</volume>:<fpage>219</fpage>&#x02013;<lpage>226</lpage>.<pub-id pub-id-type="pmid">17515850</pub-id></mixed-citation></ref></ref-list></back></article>